This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, Z. Articles by Kumar, R. Search for Related Content PubMed PubMed Citation Articles by Yang, Z. Articles by Kumar, R.

HER2 Regulation of Peroxisome Proliferator-activated Receptor (PPAR) Expression and Sensitivity of Breast Cancer Cells to PPAR Ligand Therapy¹

Departments of Molecular and Cellular Oncology [Z. Y., R. B-Y., S. B., C. J. B., R. K.], Breast Medical Oncology [G. H.], and Pathology [A. A. S.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Induction of terminal differentiation of cancer cells is an evolving novel therapeutic approach, and accordingly, peroxisome proliferator-activated receptor (PPAR), a ligand-stimulated transcription factor with differentiation-promoting activity and overexpressed in a variety of cancers, has emerged as one of the promising therapeutic targets. Because c-erbB family growth factor receptor 2 (HER2) overexpression is one of the most recognizable molecular dysfunctions in breast tumors, in the studies presented here, we explored the effect of HER2 overexpression on the status of PPAR expression and on the sensitivity of breast cancer cells to PPAR-ligand troglitazone-induced growth inhibition. We show that HER2 overexpression in MCF7 breast cancer cells enhanced the expression of PPAR-mRNA and -protein. Furthermore, PPAR expression was dramatically increased in 11 of 16 breast tumors as compared with the adjacent normal tissue. In addition, HER2 up-regulation resulted in a partial inhibition of transcriptional activity of the endogenous PPAR, stimulation to differentiation, and resistance to troglitazone-mediated inhibition of anchorage-independent growth of breast cancer cells. Conversely, down-regulation of HER2 by anti-HER2 monoclonal antibody Herceptin led to a decreased level of PPAR protein and sensitization of breast cancer cells to the inhibitory effects of troglitazone. In summary, these findings show for the first time that HER2 up-regulates PPAR expression and modulates the sensitivity of breast cancer cells to PPAR ligand therapy.

This article has been cited by other articles:

				M. Konopleva, W. Zhang, Y.-X. Shi, T. McQueen, T. Tsao, M. Abdelrahim, M. F. Munsell, M. Johansen, D. Yu, T. Madden, et al. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Mol. Cancer Ther., February 1, 2006; 5(2): 317 - 328. [Abstract] [Full Text] [PDF]

				L. D. Yee, D. C. Young, T. J. Rosol, A. M. VanBuskirk, and S. K. Clinton Dietary (n-3) Polyunsaturated Fatty Acids Inhibit HER-2/neu-Induced Breast Cancer in Mice Independently of the PPAR{gamma} Ligand Rosiglitazone J. Nutr., May 1, 2005; 135(5): 983 - 988. [Abstract] [Full Text] [PDF]

				Z. Yang, C. J. Barnes, and R. Kumar Human Epidermal Growth Factor Receptor 2 Status Modulates Subcellular Localization of and Interaction with Estrogen Receptor {alpha} in Breast Cancer Cells Clin. Cancer Res., June 1, 2004; 10(11): 3621 - 3628. [Abstract] [Full Text] [PDF]